Digital therapeutics (DTx) are increasingly being recognized and adopted into national frameworks around the world to improve patient care. To answer common questions about these products, DTA developed country-specific resources to educate patients, clinicians, policymakers, and payors about DTx products and their value across global regions.
Country-specific DTx Briefs: To introduce digital therapeutics to patients, clinicians, policymakers, and payors, DTA created a set of high-level overview briefs to answer common questions about DTx products. These resources include country-specific regulatory information and have been translated into the official languages of the below countries.
These country-specific DTx briefs include information on:
DTx Regulatory and Reimbursement Pathways: These pathways help policymakers and DTx manufacturers: understand the current landscape of how DTx products are recognized, regulated, and funded in specific countries; identify commonalities and differences across national jurisdictions; determine potential obstacles to overcome; and develop strategic approaches to ensure appropriate patient access to clinically-validated therapies.
As regulatory and product access pathways continue to evolve within the following countries, these documents will be updated to reflect critical changes.